US20170035705A1 - Detrusor hyperactivity with impaired contractility ameliorating agent - Google Patents

Detrusor hyperactivity with impaired contractility ameliorating agent Download PDF

Info

Publication number
US20170035705A1
US20170035705A1 US14/817,318 US201514817318A US2017035705A1 US 20170035705 A1 US20170035705 A1 US 20170035705A1 US 201514817318 A US201514817318 A US 201514817318A US 2017035705 A1 US2017035705 A1 US 2017035705A1
Authority
US
United States
Prior art keywords
detrusor
acid
dhic
contractility
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/817,318
Other languages
English (en)
Inventor
Yukio Hayashi
Takahisa NOMA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Priority to US14/817,318 priority Critical patent/US20170035705A1/en
Assigned to TAHIO PHARMACETUICAL CO., LTD. reassignment TAHIO PHARMACETUICAL CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HAYASHI, YUKIO, NOMA, Takahisa
Assigned to TAIHO PHARMACEUTICAL CO., LTD. reassignment TAIHO PHARMACEUTICAL CO., LTD. CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE ASSIGNEE'S NAME PREVIOUSLY RECORDED ON REEL 036829 FRAME 0239. ASSIGNOR(S) HEREBY CONFIRMS THE TAHIO SHOULD BE CORRECTED TO TAIHO. Assignors: HAYASHI, YUKIO, NOMA, Takahisa
Priority to US15/155,526 priority patent/US9687457B2/en
Priority to KR1020187006188A priority patent/KR102076137B1/ko
Priority to JP2017533103A priority patent/JP6328856B2/ja
Priority to EP16833066.0A priority patent/EP3332779B1/en
Priority to ES16833066T priority patent/ES2836685T3/es
Priority to MYPI2018700358A priority patent/MY197287A/en
Priority to KR1020197034935A priority patent/KR20190134825A/ko
Priority to RU2018107515A priority patent/RU2714444C2/ru
Priority to TW105124867A priority patent/TWI668005B/zh
Priority to MX2018001518A priority patent/MX2018001518A/es
Priority to CA2994648A priority patent/CA2994648C/en
Priority to CN201680045566.3A priority patent/CN107921011A/zh
Priority to BR112017028381-6A priority patent/BR112017028381A2/pt
Priority to SG11201710583RA priority patent/SG11201710583RA/en
Priority to AU2016301689A priority patent/AU2016301689B2/en
Priority to PCT/JP2016/072753 priority patent/WO2017022787A1/ja
Publication of US20170035705A1 publication Critical patent/US20170035705A1/en
Priority to US15/599,890 priority patent/US20170252307A1/en
Priority to PH12018500176A priority patent/PH12018500176A1/en
Priority to HK18106741.9A priority patent/HK1247106A1/zh
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Definitions

  • the present invention relates to a method for treating detrusor hyperactivity with impaired contractility (hereinafter referred to as “DHIC”), comprising the step of administering a therapeutically effective amount of 3-(15-hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexene-1-one, a salt thereof, or a solvate thereof.
  • DHIC detrusor hyperactivity with impaired contractility
  • Compound 1 of the present invention is a compound having a structure represented by Formula (1) below.
  • Patent Document 1 discloses that a cyclohexenone long-chain alcohol comprising the compound represented by Formula (1) has an effect of promoting neurite growth, and thus is useful as a preventive and/or therapeutic agent for brain disorders such as dementia.
  • Patent Document 2 discloses that a cyclohexenone long-chain alcohol comprising the compound represented by Formula (1) is useful as a therapeutic agent for treating dysuria.
  • detrusor In normal micturition function, detrusor doesn't contract during storage phase (urine can be reserved in bladder), and contracts during only voiding phase. In storage dysfunction disease (overactive bladder), detrusor overactive occurs during storage phase, so, urine can't be reserved fully in bladder. Medicines, such as an anti-cholinergic agent and a ⁇ receptor agonist, are effective for storage dysfunction disease. While on the other hand, in urine-voiding dysfunction disease (underactive bladder), an increased residual urine volume is a problem. Medicines, such as a cholinesterase inhibitor and a cholinergic agonist, are used for urine-voiding dysfunction disease.
  • Non-patent Document 1 Non-patent Document 2
  • Non-patent Document 3 an effective agent for underactive bladder is invalidity or detrimental against overactive bladder
  • DHIC is a disorder which presents both of detrusor overactive and detrusor impaired contractility in the body of the same individual (Non-patent Document 4, Non-patent Document 5). Because detrusor overactive occurs additionally with a residual urine volume increased by detrusor impaired contractility, it induces high-pressure during storage phase and incontinence. Further, if such condition is left unattended without appropriate care, it results in a sever disease such as urinary-tract infection, upper urinary tract disorder, or renal dysfunction.
  • DHIC is clinically diagnosed by confirming coexistence of detrusor overactive during storage phase and detrusor impaired contractility during voiding phase using Pressure-Flow Study (nomogram analysis is useful for the diagnosis) (Non-patent Document 4, Non-patent Document 5).
  • Non-patent Document 6 Non-patent Document 6
  • overactive bladder is diagnosed by subjective symptom (urgency, incontinence, pollakiuria etc.)
  • underactive bladder is diagnosed by subjective symptom (forceless urinary stream, terminal dribbling, retarded micturition, abdominal straining to urinate, a feeling of residual urine, urinary retention etc.), uroflowmetry, and measurement of residual urine volume etc.
  • DHIC can be diagnosed by confirming coexistence of both the disorders.
  • Non-patent Document 8 the therapeutic agent for DHIC which presents both of detrusor overactivity and detrusor impaired contractility in the body of the same individual. It was recently reported that an ⁇ 1-blocker such as Tamsulosin etc., which was effective on urine-voiding dysfunction (underactive bladder), was also effective on overactive bladder (Non-patent Document 8).
  • An object of the present invention is to provide a method for treating DHIC by improving both of detrusor overactivity and detrusor impaired contractility.
  • the present invention provides a method for treating a disorder that presents both detrusor overactivity and detrusor impaired contractility, comprising the step of administering a therapeutically effective amount of 3-(15-hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexene-1-one, a salt thereof, or a solvate thereof.
  • the present invention provides a method for treating DHIC, comprising the step of administering a therapeutically effective amount of 3-(15-hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexene-1-one, a salt thereof, or a solvate thereof, to a patient with DHIC.
  • the present invention provides a method of ameliorating a disease that presents both of detrusor underactivity and detrusor hyperactivity, using 3-(15-hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexene-1-one, a salt thereof, or a solvate thereof, to a patient that presents both of detrusor underactivity and detrusor hyperactivity.
  • the present invention enables effective treatments of DHIC.
  • FIG. 1 shows representative cystometry charts of rat dysuria model that presents DHIC.
  • FIG. 2 shows the effects of Compound 1 of the present and ⁇ 1-blocker (Tamsulosin) on detrusor contractility in rat dysuria model that presents DHIC.
  • Compound 1 of the present invention is a known compound, and is produced by, for example, the method disclosed in International Publication WO1999/008987.
  • treatment means maintenance treatment for alleviating the symptoms and preventing the recurrence by improving a disease that presents both of detrusor overactivity and detrusor underactivity, especially, maintenance treatment for alleviating the symptoms and preventing the recurrence by ameliorating DHIC.
  • a treatment of DHIC means a method of ameliorating a disease that presents both of detrusor overactivity during storage phase and detrusor impaired contractility during voiding phase.
  • Compound 1 of the present invention may be formed acid adduct salt, or base adduct salt.
  • the present include the present invention to the extent that the salt is a pharmaceutically acceptable salt thereof.
  • the salt includes an acid adduct salt with an inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, or phosphoric acid etc.; an acid adduct salt with an organic acid such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, citric acid, tartaric acid, carbonic acid, picric acid, methansulfonic acid, p-toluenesulfonic acid, or glutamic acid etc.; salt with an inorganic base such as sodium, potassium, magnesium, calcium, or aluminum etc.; salt with an organic base such as methylamine, ethylamine, meglumine,
  • Examples of the solvent of the solvate of Compound 1 of the present invention include water, methanol, ethanol, isopropanol, acetonitrile, tetrahydrofuran, ethyl acetate, toluene, hexane, acetone, methyl ethyl ketone, and methyl isobutyl ketone etc.
  • 3-(15-hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexene-1-one, a salt thereof, or a solvate thereof of the present invention can be prepared into various dosage forms by using known preparation methods using a pharmaceutically acceptable carrier.
  • the dosage form is not particularly limited, and examples thereof include oral agents such as tablets, coated tablets, pills, powdered drugs, granules, capsules, liquids, suspensions, or emulsions; and parenteral agents such as injections or suppositories.
  • examples of carrier include excipients such as lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, or silicic acid; binders such as water, ethanol, propanol, cornstarch, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethylcellulose, shellac, methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, potassium phosphate, or polyvinyl pyrrolidone; disintegrants such as dry starch, sodium alginate, powdered agar, powdered laminaran, sodium hydrogencarbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid ester, sodium lauryl sulfate, stearic acid monoglyceride, or lactose; disintegration inhibitors such as sucrose, stearic acid, cacao butter, or hydrogenated oils; absorbefacients such as quaternary ammonium salts or sodium la
  • examples of the carrier include excipients such as glucose, lactose, starch, cacao butter, hardened vegetable oil, kaolin, or talc; binders such as gum arabic powder, tragacanth powder, gelatin, or ethanol; and disintegrators such as laminaran or agar.
  • Capsules are usually prepared in a standard method by blending the drug with one or more carriers as exemplified above, and encapsulating the mixture into hard gelatin capsules, soft capsules, etc.
  • an internal liquid medicine, a syrup, an elixir, or the like may be prepared by a standard method using sweetening/flavoring agent, buffer, stabilizer, etc.
  • sweetening/flavoring agents include sucrose, wild orange peel, citric acid, and tartaric acid
  • buffers include sodium citrate
  • stabilizers include tragacanth, gum arabic, and gelatin.
  • examples of usable carriers include polyethylene glycol, cacao butter, higher alcohols, esters of higher alcohols, gelatin, and semisynthetic glycerides.
  • the liquids, emulsions, and suspensions are preferably sterilized and rendered isotonic to the blood.
  • diluents for preparing such dosage forms include water, aqueous lactic acid solution, ethanol, propylene glycol, macrogols, ethoxylated isostearyl alcohol, polyoxyethylenated isostearyl alcohol, and polyoxyethylene sorbitan fatty acid ester.
  • sodium chloride, glucose, or glycerin in an amount sufficient to prepare an isotonic solution may be added to the pharmaceutical formulation.
  • general solubilizers, buffers, anesthetics, and the like may also be added to the pharmaceutical formulation.
  • coloring agents, preservatives, aromatics, flavors, sweetening agents, or other medicinal products may be incorporated, if necessary, into the pharmaceutical formulations.
  • the method for administering the DHIC ameliorating agent of the present invention is not particularly limited, and is suitably selected according to the dosage form thereof, the age, gender, and other conditions of the patient, the severity of the symptoms of the patient, and the like.
  • tablets, pills, powdered drugs, granules, capsules, liquids, suspensions, and emulsions are orally administered.
  • the injections are intravenously administered singly, or as a mixture with a general infusion liquid such as liquid glucose or an amino acid liquid. Further, as necessary, the injections are singly administered intra-arterially, intramuscularly, intradermally, subcutaneously, or intraperitoneally.
  • the suppositories are intrarectally administered.
  • the amount of the compound of the present invention or a salt thereof to be incorporated into each of the above dosage unit form depends on the symptoms of the target patient, or depends on the drug form; however, the amount per dosage unit form is generally preferably about 0.005 to 1,000 mg, more preferably 1 to 800 mg, further preferably 5 to 500 mg for oral agents; about 0.001 to 500 mg, more preferably 0.02 to 400 mg, further preferably 1 to 250 mg for injections; and about 0.01 to 1,000 mg, more preferably 1 to 800 mg, further preferably 5 to 500 mg for suppositories.
  • the daily dose for an adult of the drug to be administered with the above dosage form is generally about 0.005 to 5,000 mg, preferably 0.01 to 2,000 mg, more preferably 10 to 1600 mg, further preferably 20 to 800 mg, although such doses depend on the symptom, body weight, age, gender, etc., of the patient.
  • the daily dose is preferably taken at one time, or divided into two to four administrations.
  • the models were produced by partial ligation ( ⁇ 1.57 mm) of urethra in rats (9 weeks, female, Sprague-Dawley). Six weeks after preparation of the model, the rats were released the ligation. The next day, the intravesical pressure and the voided volume were measured under awake condition. And the detrusor contractility during voiding phase was evaluated by nomogram analysis using Qmax and Pdet. Additionally, the detrusor overactivity, as index of overactive bladder, and the increase of residual urine volume, as index of underactive bladder, were evaluated.
  • FIG. 1 shows representative cystometry charts.
  • the dysuria model rat control
  • sham rat there is the characteristics of detrusor hyperactivity with impaired contractility that are characterized by remarkable overactivity and increased residual urine volume (Table 1).
  • Non-patent Document 9 Urol Clin North Am, 17, p 553-566 (1990)
  • the plot of control group is positioned in a position relatively close to the origin compared to it of sham group (the distance from the origin: Sham group 24.75 ⁇ 3.14, control group 4.24 ⁇ 0.53, p ⁇ 0.05)
  • the distance from the origin: Sham group 24.75 ⁇ 3.14, control group 4.24 ⁇ 0.53, p ⁇ 0.05 it is judged that reduction of detrusor contractility occurs in the rat dysuria model ( FIG. 2 ).
  • the dysuria models in this example were prepared in the same manner as in Test Example 1.
  • the test drugs (vehicle: 6% Gelucire, Compound 1 of the present invention 10 mg/kg) were orally administered to each group after two weeks from the preparation of the models twice a day for four weeks. On the day of the final administration, the rats were released the ligation of urethra. The next day, the intravesical pressure and the voided volume were measured using cystometry under conscious condition. The detrusor overactivity, as an index of overactive bladder, and the increase of residual urine volume, as an index of underactive bladder, were evaluated. Additionally, the detrusor contractility during voiding phase was evaluated by nomogram analysis using Qmax and Pdet.
  • the rats were released the ligation of urethra at six weeks after the preparation of the model.
  • the next day the intravesical pressure and the voided volume were measured using cystometry under conscious condition.
  • the detrusor contractility during voiding phase was evaluated by nomogram analysis using Qmax and Pdet. Tamsulosin (3 ⁇ g/kg) was administered intravenously to the dysuria rat at the evaluation (six weeks after preparation of the model).
  • ⁇ 1 blocker Tropsulosin
  • the dysuria models in the present example were prepared by treating 10-week-old female Wistar rats with streptozotocin (65 mg/kg, i.p.). From four weeks after the preparation of the models, Tamsulosin (1 ⁇ g/kg/hr) was administered subcutaneously using osmotic pump. Four weeks after the implant of osmotic pump, the intravesical pressure and the voided volume were measured using cystometry under urethane anesthesia condition. And the residual urine volume, as an index of underactive bladder, was evaluated.
  • Table 2 shows the results. In comparison with the Sham group, significant increase of the residual urine volume, which is an index of underactive bladder, was observed in the control group (eight weeks after the development of the disease in the models). Tamsulosin showed significant reduction on the increase of residual urine volume which was observed in the control group.
  • Compound 1 of the present invention shows effect for ameliorating both dysfunctions in DHIC that detrusor overactivity and detrusor impaired contractility coexist (Test Example 2). Therefore, it is suggested that Compound 1 of the present invention is a useful therapeutic agent for DHIC (Test Example 2).

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US14/817,318 2015-08-04 2015-08-04 Detrusor hyperactivity with impaired contractility ameliorating agent Abandoned US20170035705A1 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
US14/817,318 US20170035705A1 (en) 2015-08-04 2015-08-04 Detrusor hyperactivity with impaired contractility ameliorating agent
US15/155,526 US9687457B2 (en) 2015-08-04 2016-05-16 Detrusor hyperactivity with impaired contractility ameliorating agent
AU2016301689A AU2016301689B2 (en) 2015-08-04 2016-08-03 Ameliorating agent for detrusor hyperactivity with impaired contractility
PCT/JP2016/072753 WO2017022787A1 (ja) 2015-08-04 2016-08-03 収縮力低下随伴性排尿筋過活動改善剤
TW105124867A TWI668005B (zh) 2015-08-04 2016-08-03 逼尿肌過度活動伴收縮力降低之改善劑
CA2994648A CA2994648C (en) 2015-08-04 2016-08-03 Ameliorating agent for detrusor hyperactivity with impaired contractility
EP16833066.0A EP3332779B1 (en) 2015-08-04 2016-08-03 Ameliorating agent for detrusor hyperactivity with impaired contractility
ES16833066T ES2836685T3 (es) 2015-08-04 2016-08-03 Agente para aliviar la hiperactividad del detrusor con deterioro de la contractilidad
MYPI2018700358A MY197287A (en) 2015-08-04 2016-08-03 Ameliorating agent for detrusor hyperactivity with impaired contractility
KR1020197034935A KR20190134825A (ko) 2015-08-04 2016-08-03 수축력 저하 수반성 배뇨근 과활동 개선제
RU2018107515A RU2714444C2 (ru) 2015-08-04 2016-08-03 Средство, снижающее интенсивность гиперактивности детрузора с нарушенной сократимостью
KR1020187006188A KR102076137B1 (ko) 2015-08-04 2016-08-03 수축력 저하 수반성 배뇨근 과활동 개선제
MX2018001518A MX2018001518A (es) 2015-08-04 2016-08-03 Agente mejorador para hiperactividad del detrusor con deterioro de la contractilidad.
JP2017533103A JP6328856B2 (ja) 2015-08-04 2016-08-03 収縮力低下随伴性排尿筋過活動改善剤
CN201680045566.3A CN107921011A (zh) 2015-08-04 2016-08-03 逼尿肌过度活动伴收缩功能受损的改善剂
BR112017028381-6A BR112017028381A2 (pt) 2015-08-04 2016-08-03 agente para melhora da hiperatividade do músculo detrusor com contratilidade prejudicada
SG11201710583RA SG11201710583RA (en) 2015-08-04 2016-08-03 Ameliorating agent for detrusor hyperactivity with impaired contractility
US15/599,890 US20170252307A1 (en) 2015-08-04 2017-05-19 Detrusor hyperactivity with impaired contractility ameliorating agent
PH12018500176A PH12018500176A1 (en) 2015-08-04 2018-01-23 Ameliorating agent for detrusor hyperactivity with impaired contractility
HK18106741.9A HK1247106A1 (zh) 2015-08-04 2018-05-24 逼尿肌過度活動伴收縮功能受損的改善劑

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/817,318 US20170035705A1 (en) 2015-08-04 2015-08-04 Detrusor hyperactivity with impaired contractility ameliorating agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/155,526 Continuation US9687457B2 (en) 2015-08-04 2016-05-16 Detrusor hyperactivity with impaired contractility ameliorating agent

Publications (1)

Publication Number Publication Date
US20170035705A1 true US20170035705A1 (en) 2017-02-09

Family

ID=57943093

Family Applications (3)

Application Number Title Priority Date Filing Date
US14/817,318 Abandoned US20170035705A1 (en) 2015-08-04 2015-08-04 Detrusor hyperactivity with impaired contractility ameliorating agent
US15/155,526 Active 2035-08-05 US9687457B2 (en) 2015-08-04 2016-05-16 Detrusor hyperactivity with impaired contractility ameliorating agent
US15/599,890 Abandoned US20170252307A1 (en) 2015-08-04 2017-05-19 Detrusor hyperactivity with impaired contractility ameliorating agent

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/155,526 Active 2035-08-05 US9687457B2 (en) 2015-08-04 2016-05-16 Detrusor hyperactivity with impaired contractility ameliorating agent
US15/599,890 Abandoned US20170252307A1 (en) 2015-08-04 2017-05-19 Detrusor hyperactivity with impaired contractility ameliorating agent

Country Status (17)

Country Link
US (3) US20170035705A1 (ko)
EP (1) EP3332779B1 (ko)
JP (1) JP6328856B2 (ko)
KR (2) KR102076137B1 (ko)
CN (1) CN107921011A (ko)
AU (1) AU2016301689B2 (ko)
BR (1) BR112017028381A2 (ko)
CA (1) CA2994648C (ko)
ES (1) ES2836685T3 (ko)
HK (1) HK1247106A1 (ko)
MX (1) MX2018001518A (ko)
MY (1) MY197287A (ko)
PH (1) PH12018500176A1 (ko)
RU (1) RU2714444C2 (ko)
SG (1) SG11201710583RA (ko)
TW (1) TWI668005B (ko)
WO (1) WO2017022787A1 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6894555B1 (ja) * 2020-07-03 2021-06-30 大鵬薬品工業株式会社 排尿症状治療剤
JP2022013721A (ja) * 2020-07-03 2022-01-18 大鵬薬品工業株式会社 排尿症状治療剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69811905T2 (de) 1997-08-13 2003-11-06 Meiji Milk Prod Co Ltd Cyclohexenon langketten alkohol und diese enthaltendes arzneimittel
JP3836684B2 (ja) * 2001-02-19 2006-10-25 明治乳業株式会社 排尿障害治療剤
RU2193401C1 (ru) * 2001-04-02 2002-11-27 Аль-Шукри Салман Хасунович Способ лечения гиперактивности мочевого пузыря
US20080033018A1 (en) * 2004-07-05 2008-02-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic Agents For Overactive Bladder
CA2595208C (en) * 2005-01-18 2013-04-23 Meiji Dairies Corporation Therapeutic agents for sensory disorders
JP2009292797A (ja) * 2008-06-09 2009-12-17 Kyoto Univ 過活動膀胱治療剤
JP2015067565A (ja) 2013-09-27 2015-04-13 大鵬薬品工業株式会社 ３−（１５−ヒドロキシペンタデシル）−２，４，４−トリメチル−２−シクロヘキセン−１−オン又はその塩を含有する医薬組成物
JP5566521B1 (ja) * 2013-09-27 2014-08-06 大鵬薬品工業株式会社 膀胱・尿道協調不全改善剤

Also Published As

Publication number Publication date
RU2714444C2 (ru) 2020-02-17
SG11201710583RA (en) 2018-01-30
EP3332779A1 (en) 2018-06-13
RU2018107515A (ru) 2019-09-05
TWI668005B (zh) 2019-08-11
PH12018500176A1 (en) 2018-07-30
CN107921011A (zh) 2018-04-17
AU2016301689B2 (en) 2018-10-04
CA2994648A1 (en) 2017-02-09
KR20190134825A (ko) 2019-12-04
ES2836685T3 (es) 2021-06-28
RU2018107515A3 (ko) 2019-09-05
MY197287A (en) 2023-06-09
JPWO2017022787A1 (ja) 2018-04-26
JP6328856B2 (ja) 2018-05-23
CA2994648C (en) 2020-04-07
KR102076137B1 (ko) 2020-02-11
WO2017022787A1 (ja) 2017-02-09
TW201717924A (zh) 2017-06-01
KR20180038003A (ko) 2018-04-13
MX2018001518A (es) 2018-04-24
US9687457B2 (en) 2017-06-27
US20170252307A1 (en) 2017-09-07
BR112017028381A2 (pt) 2018-08-28
AU2016301689A1 (en) 2018-01-25
EP3332779B1 (en) 2020-10-28
EP3332779A4 (en) 2019-03-13
HK1247106A1 (zh) 2018-09-21
US20170035706A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
US8642661B2 (en) Pharmaceutical combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonists
US20090068290A1 (en) Bifeprunox doses for treating schizophrenia
US9687457B2 (en) Detrusor hyperactivity with impaired contractility ameliorating agent
US11938102B2 (en) S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis
JP2010501626A (ja) 統合失調症を処置するためのビフェプルノックス用量
EP3111934B1 (en) Progress-suppressing or improving agent for chronic kidney disease
US9271948B2 (en) Agent for improving vesicourethral dyssynergia
US20100331361A1 (en) Pharmaceutical composition containing alpha-adrenergic receptor antagonist and an anti-muscarinic agent and method of improving lower urinary tract symptoms associated with prostatic hypertrophy
US9603845B2 (en) Prophylactic agent and/or therapeutic agent for stress urinary incontinence
KR20240012516A (ko) 간질성 방광염/방광통증 증후군을 치료하는 방법
JP2008513430A (ja) 月経前症候群および月経前不快気分障害の処置のためのピンドロール
WO2024141073A1 (en) Pharmaceutical combinations and compositions, and methods of use thereof
CN112512526B (zh) 化合物a与化合物b联合在制备治疗痛风或高尿酸血症的药物中的用途
US20230255903A1 (en) Urinary symptom therapeutic agent

Legal Events

Date Code Title Description
AS Assignment

Owner name: TAHIO PHARMACETUICAL CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HAYASHI, YUKIO;NOMA, TAKAHISA;REEL/FRAME:036829/0239

Effective date: 20150818

AS Assignment

Owner name: TAIHO PHARMACEUTICAL CO., LTD., JAPAN

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE ASSIGNEE'S NAME PREVIOUSLY RECORDED ON REEL 036829 FRAME 0239. ASSIGNOR(S) HEREBY CONFIRMS THE TAHIO SHOULD BE CORRECTED TO TAIHO;ASSIGNORS:HAYASHI, YUKIO;NOMA, TAKAHISA;REEL/FRAME:037701/0132

Effective date: 20150818

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION